Literature DB >> 12608545

Direct formation of nanospheres from amphiphilic beta-cyclodextrin inclusion complexes.

Erem Memişoğlu1, Amélie Bochot, Meral Ozalp, Murat Sen, Dominique Duchêne, A Atilla Hincal.   

Abstract

PURPOSE: The aim of this work was to develop and characterize a highly loaded nanoparticulate system based on amphiphilic beta-cyclodextrins (CDs) to facilitate the parenteral administration of poorly soluble antifungal model drugs bifonazole and clotrimazole.
METHODS: Inclusion complexes were characterized with spectroscopic techniques. Particle size distribution of nanospheres were determined by photon correlation spectroscopy (PCS). Nanospheres were assessed for hemolytic activity. Entrapped and released drug quantities were determined and minimum inhibitory concentration (MIC) values of drugs, amphiphilic beta-CDs, and drug loaded nanospheres were evaluated.
RESULTS: 1:1 inclusion complexes of model drugs with amphiphilic beta-CDs gave nanospheres <300 nm (polydispersity index < 0.15) by nanoprecipitation technique without using surfactants. By direct preparation from preformed inclusion complexes, loading was increased 2- to 8-fold depending on CD type and loading technique. Conventionally loaded CD nanospheres displayed immediate release whereas preloaded and highly loaded nanospheres liberated model drugs over a period of 1 h reducing the initial burst effect. MIC values of bifonazole and clotrimazole were lowered significantly when associated to amphiphilic beta-CD nanospheres.
CONCLUSION: Amphiphilic beta-CDs form nonsurfactant, highly loaded nanospheres with lower hemolytic activity than that of natural CDs directly from inclusion complexes. They enhanced solubility and subsequently therapeutic efficacy of the model drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12608545     DOI: 10.1023/a:1022263111961

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Industrial Applications of Cyclodextrins.

Authors:  Allan R. Hedges
Journal:  Chem Rev       Date:  1998-07-30       Impact factor: 60.622

2.  Cyclodextrin-based controlled drug release system.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-03-01       Impact factor: 15.470

Review 3.  Cyclodextrins--enabling excipients: their present and future use in pharmaceuticals.

Authors:  D O Thompson
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1997       Impact factor: 4.889

4.  Evaluation of the hydrophobic drug loading characteristics in nanoprecipitated amphiphilic cyclodextrin nanospheres.

Authors:  E Lemos-Senna; D Wouessidjewe; S Lesieur; F Puisieux; G Couarraze; D Duchêne
Journal:  Pharm Dev Technol       Date:  1998-02       Impact factor: 3.133

5.  Formation and antimicrobial activity of complexes of beta-cyclodextrin and some antimycotic imidazole derivatives.

Authors:  H Van Doorne; E H Bosch; C F Lerk
Journal:  Pharm Weekbl Sci       Date:  1988-04-22

6.  Amphiphilic beta-cyclodextrins modified on the primary face: synthesis, characterization, and evaluation of their potential as novel excipients in the preparation of nanocapsules.

Authors:  Erem Memişoğlu; Amélie Bochot; Murat Sen; Daniel Charon; Dominique Duchêne; A Atilla Hincal
Journal:  J Pharm Sci       Date:  2002-05       Impact factor: 3.534

7.  Cyclodextrins and carrier systems.

Authors:  D Duchêne; D Wouessidjewe; G Ponchel
Journal:  J Control Release       Date:  1999-11-01       Impact factor: 9.776

8.  In vitro studies of a new imidazole antimycotic, bifonazole, in comparison with clotrimazole and miconazole.

Authors:  H Yamaguchi; T Hiratani; M Plempel
Journal:  Arzneimittelforschung       Date:  1983
  8 in total
  9 in total

1.  Fluid bed drying of guarana (Paullinia cupana HBK) extract: effect of process factors on caffeine content.

Authors:  Renata S Pagliarussi; Jairo K Bastos; Luis A P Freitas
Journal:  AAPS PharmSciTech       Date:  2006-06-16       Impact factor: 3.246

2.  Formulation, characterization, and clinical evaluation of microemulsion containing clotrimazole for topical delivery.

Authors:  Fahima M Hashem; Dalia S Shaker; Mohamed Khalid Ghorab; Mohamed Nasr; Aliaa Ismail
Journal:  AAPS PharmSciTech       Date:  2011-07-02       Impact factor: 3.246

3.  Clotrimazole-cyclodextrin based approach for the management and treatment of Candidiasis - A formulation and chemistry-based evaluation.

Authors:  Noorullah Naqvi Mohammed; Pankaj Pandey; Nayaab S Khan; Khaled M Elokely; Haining Liu; Robert J Doerksen; Michael A Repka
Journal:  Pharm Dev Technol       Date:  2015-04-29       Impact factor: 3.133

Review 4.  Cyclodextrins in drug delivery: an updated review.

Authors:  Rajeswari Challa; Alka Ahuja; Javed Ali; R K Khar
Journal:  AAPS PharmSciTech       Date:  2005-10-14       Impact factor: 3.246

Review 5.  Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective.

Authors:  Jianxiang Zhang; Peter X Ma
Journal:  Adv Drug Deliv Rev       Date:  2013-05-11       Impact factor: 15.470

Review 6.  Self-assemblies of amphiphilic cyclodextrins.

Authors:  Michel Roux; Bruno Perly; Florence Djedaïni-Pilard
Journal:  Eur Biophys J       Date:  2007-07-31       Impact factor: 1.733

Review 7.  Nano-Assemblies of Modified Cyclodextrins and Their Complexes with Guest Molecules: Incorporation in Nanostructured Membranes and Amphiphile Nanoarchitectonics Design.

Authors:  Leïla Zerkoune; Angelina Angelova; Sylviane Lesieur
Journal:  Nanomaterials (Basel)       Date:  2014-08-20       Impact factor: 5.076

8.  Improvement of solubility and dissolution properties of clotrimazole by solid dispersions and inclusion complexes.

Authors:  Gehan Balata; M Mahdi; Rania Abu Bakera
Journal:  Indian J Pharm Sci       Date:  2011-09       Impact factor: 0.975

9.  Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery.

Authors:  Gamze Varan; Juan M Benito; Carmen Ortiz Mellet; Erem Bilensoy
Journal:  Beilstein J Nanotechnol       Date:  2017-07-13       Impact factor: 3.649

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.